Breaking the Shield: Why Biofilms May Be the Hidden Culprit Behind Recurrent SIBO and UTIs

A functional medicine perspective on persistent biofilms

By Dr. Cristiana Coneru, MD, FRSM, FRCEM, CFMP, HCTP, Dip CNM, NBC‑HWC Founder of Health Visioning

www.healthvisioning.com

We often blame recurring symptoms on bad luck, a weak immune system, or the return of an infection that we thought had finally been cleared. The bloating comes back. The urinary symptoms return. Another round of treatment helps for a while, only for the cycle to begin again.

If you've ever felt frustrated, exhausted, or discouraged by this pattern, you're not alone.

What many people don't realise is that the problem may not be the bacteria themselves, but the protective shield they hide behind. Known as biofilms, these complex microbial communities can allow bacteria to evade the immune system, resist treatment, and persist in the body long after symptoms temporarily improve (Zhao et al., 2023).

From a functional medicine perspective, understanding biofilms can be a crucial missing piece of the puzzle. In conditions such as Small Intestinal Bacterial Overgrowth (SIBO) and recurrent urinary tract infections (UTIs), these microbial fortresses may help explain why conventional approaches sometimes fail to deliver lasting relief.

The consequences of this hidden survival strategy are not merely theoretical. They are reflected in the stories of countless patients who experience temporary improvement, only to find themselves caught in a cycle of relapse and retreatment.

In this article, we'll explore what biofilms are, how they may contribute to chronic and recurring infections, and the evidence-informed strategies that are being explored to disrupt them, always with an honest look at how strong that evidence really is.

Why Do Recurrent SIBO and UTIs Keep Coming Back? The Clinical Frustration

For many patients, recurrent SIBO and UTIs are far more than isolated infections. They become a recurring pattern that erodes confidence, disrupts daily life, and leaves individuals questioning why lasting relief seems so difficult to achieve.

It is a scenario played out daily in functional medicine practices worldwide: a patient sits across from you, visibly exhausted, clutching a thick folder of past lab results. Their story is often strikingly familiar. They experience a flare-up of intense bladder urgency or debilitating abdominal bloating. They complete a course of targeted antimicrobials or antibiotics and, for a brief period, their symptoms improve. Hope returns. Life begins to feel normal again.

Then, without warning, the symptoms return.

The burning resurfaces. The bloating and post-prandial distension creep back. Another treatment cycle begins, only to be followed by yet another relapse.

This is the exhausting and deeply demoralising reality of recurrent UTIs and SIBO. Patients caught in this cycle often begin to blame themselves. They scrutinise every meal, question their stress levels, and wonder whether they are somehow failing to do something right.

As clinicians, it is vital to offer immediate and genuine reassurance: the failure does not lie with the patient, nor does it necessarily reflect a weak or inadequate immune response.

The clinical reality is often more complex than it first appears. When symptoms return shortly after treatment, the immediate assumption is frequently antimicrobial resistance or the need for a stronger intervention. Antibiotics are changed, herbal protocols intensified, or treatment durations extended.

Yet the underlying problem may not be simply microbial. It may also be structural.

We may be attempting to solve a mechanical problem with chemical solutions. Bacteria living in a biofilm build a microscopic fortress that can protect them from both antimicrobial agents and immune surveillance. Until that protective architecture is addressed, even the most aggressive treatment strategies may struggle to achieve lasting success.

To break the cycle of relapse, it makes sense to look beyond the bacteria themselves and consider the hidden structure that may allow them to persist.

What Is a Biofilm? (The Invisible Shield)

To understand why chronic SIBO and recurrent UTIs can defy conventional treatment, we have to look past the individual bacterial cell and examine how microbes behave in nature. In standard medical education, we are often trained to picture bacteria as free-floating, solitary organisms, what microbiologists call planktonic bacteria. Bacteria can certainly live this way, but in many chronic and device-related infections a large share of them are thought to live as biofilms instead (Schulze et al., 2021; Zhao et al., 2023). They seek survival through collaboration.

At its core, a biofilm is a protective, self-produced community. When bacteria attach to a surface, whether that is the lining of the bladder or the surface of the small intestine, they can begin to secrete a sticky, complex matrix known as an Extracellular Polymeric Substance (EPS).

Think of this EPS matrix as a molecular "slime shield." It is a dense mesh built from complex sugars (polysaccharides), proteins and extracellular DNA, with smaller amounts of lipids (Di Martino, 2018). Once embedded in this matrix, bacteria are partly shielded from their environment. The matrix acts as a physical barrier that can slow the penetration of antimicrobials and make it harder for immune cells to reach the bacteria beneath (Zhao et al., 2023).

A fortress also needs mortar. In laboratory work on Pseudomonas aeruginosa biofilms, divalent cations such as calcium, magnesium and iron help hold the matrix together, and removing them with a chelator makes the biofilm disperse and its bacteria more vulnerable (Banin et al., 2006). Whether the same applies to the biofilms of SIBO or UTI in people is not yet established, but it explains why "mineral mortar" has become a target of interest.

Why Can Standard Tests Come Back Clean?

When a symptomatic patient provides a urine sample for a standard culture, the laboratory relies on catching bacteria that are shed into the fluid. Bacteria that sit in biofilms, or inside the cells of the bladder wall, may not be present at levels a standard culture can detect. A review in Urology describes patients with persistent lower urinary tract symptoms and negative urine cultures, and proposes that undetected bladder-wall invasion and intracellular bacterial communities may be one cause (Scott et al., 2015).

The result can be a painful diagnostic blind spot: the patient is in real pain, yet their lab reports come back clean. Too often, patients are then told that their symptoms are "all in their head." A negative culture does not mean there are no symptoms, and it does not always mean there is nothing to find.

Biofilms and Recurrent SIBO: What Do We Know?

When we translate the science of biofilms into the complex ecosystem of the gastrointestinal tract, we can see why Small Intestinal Bacterial Overgrowth (SIBO), and its methane-predominant counterpart now called intestinal methanogen overgrowth (IMO), can be difficult to clear. In a healthy gut, the small intestine maintains a relatively low microbial population.

Treatment matters, but it is not the whole story. Rifaximin is effective in many patients: a meta-analysis of 32 studies found an overall breath-test eradication rate of about 71%, although the quality of the included studies was generally poor (Gatta & Scarpignato, 2017). Herbal antimicrobial protocols also show promise. In one retrospective study, breath-test normalisation was 46% with two proprietary herbal formulas and 34% with rifaximin, a difference that was not statistically significant (Chedid et al., 2014). Because that study was retrospective and non-randomised, it should be read as encouraging rather than definitive. In practice, many people, and the clinicians who treat them, report symptoms returning after a course finishes.

A Possible Role for Biofilms

One proposed explanation is that some of the bacteria remain on the intestinal lining within a biofilm. A 2025 commentary reported endoscopically visible biofilm-like layers in the terminal ileum in 24 of 40 patients (60%) with diarrhoea- or mixed-predominant irritable bowel syndrome, and these findings were associated with a positive lactulose breath test (Baumgartner & Gasche, 2025). This is intriguing, but it is an observation, not proof that biofilms cause SIBO relapse.

It is also important to be transparent that the link between SIBO and irritable bowel syndrome is still debated. In a well-known study using small-bowel culture, SIBO by the standard definition was found in 4% of patients with IBS and 4% of healthy controls (Posserud et al., 2007), although mildly raised bacterial counts were more common in IBS. Biofilms are a hypothesis worth taking seriously, not a settled explanation.

If biofilms are involved, it would make sense that antimicrobials might clear free-floating bacteria in the lumen more readily than bacteria embedded on the mucosa, and that symptoms could recur once treatment stops. This remains a plausible hypothesis, supported mainly by general biofilm biology (Schulze et al., 2021) rather than by direct SIBO data.

Biofilm-forming bacteria are also pro-inflammatory in many settings (Schulze et al., 2021), and it has been suggested that a biofilm on the gut wall could contribute to local inflammation and increased intestinal permeability. That connection in SIBO remains a hypothesis, and direct human evidence for it is limited.

Biofilms and Chronic UTIs: Are Some "New" Infections Actually Old Ones?

When we pivot our clinical focus from the gut to the bladder, we find a similar story. For decades, recurrent urinary tract infections have largely been understood as a series of fresh infections introduced from the outside.

When a patient presents with four, six, or eight UTIs in a single year, they are often told they simply have "poor hygiene," or that they keep introducing new bacteria into the urethra. That explanation can inflict an unfair psychological burden on the patient, and the research suggests it is incomplete.

In a substantial proportion of women, recurrent cystitis is caused by the same bacterial strain as the original infection (Rosen et al., 2007). A matching strain does not prove the bacteria were hiding in the bladder wall, since the gut can also re-seed the urinary tract, but it raises the real possibility that some recurrences are relapses rather than new infections. Recent reviews describe biofilm formation as a major contributor to recurrent UTI (Abu Lila et al., 2023).

Intracellular Bacterial Communities (IBCs)

One proposed mechanism is the formation of Intracellular Bacterial Communities (IBCs). Uropathogenic Escherichia coli (UPEC) can survive in the urinary tract by invading the cells that line the bladder, where they multiply in biofilm-like communities or persist in a dormant state, partly shielded from the immune system and from many antibiotics (Kwak et al., 2024).

The bladder wall is lined by a protective glycosaminoglycan (GAG) layer (Klingler, 2016; Poletajew et al., 2024). UPEC can reach and enter the surface (umbrella) cells of the urothelium, the bladder wall lining, and once inside they may form IBCs. Much of what we know about this sequence comes from mouse models. In humans, IBCs have been detected in the urine of about 18% of women with acute cystitis in one study, but not in the asymptomatic women tested (Rosen et al., 2007).

Inside host cells, bacteria are not easily reached by the immune system or by antibiotics that penetrate cells poorly. Such reservoirs may remain quiet for a time and then re-emerge, which could look like a "new" infection (Kwak et al., 2024). Why this happens in some people and not others is not fully understood. Hormonal changes influence the lower urinary tract (Robinson et al., 2013), and hormonal shifts, stress and sexual activity are often discussed as possible triggers, but this remains a hypothesis rather than an established mechanism.

To both the patient and the clinician, a flare-up like this looks, acts, and feels like a brand-new infection that needs another round of antibiotics. Sometimes it is. For some people, it may be an old reservoir waking up. Until better diagnostic tools and targeted treatments are available, recognising this possibility can at least change how we listen to patients with persistent or recurrent symptoms.

The Functional Medicine Toolkit: Natural Biofilm Disruptors

To break the relentless cycle of chronic SIBO and recurrent UTIs, some clinicians shift their focus from simple eradication to structural dismantling, adding agents that may degrade the matrix, interfere with bacterial communication, or reduce attachment to the bladder lining.

How strong is the evidence? The support for these agents varies widely. The human data on biofilm disruptors in SIBO come mainly from one single-clinic retrospective chart review (Ruscio et al., 2025), conducted by clinicians associated with an institute that also sells related products. For the urinary tract, most of the evidence below comes from laboratory studies or animal case reports. Please read this section as a map of what is being explored, not as proven treatment. 

The following overview summarises these agents by proposed mechanism:

 1. Matrix Digesters (Systemic Enzymes)

Proteolytic and fibrinolytic enzymes such as serrapeptase, nattokinase and lumbrokinase are used by some clinicians because the EPS matrix contains proteins. In a laboratory study, serrapeptase reduced E. coli biofilms, with effects on curli fibres (a protein component), lipopolysaccharides and phosphate metabolism (Katsipis et al., 2025). That study was in vitro, and it did not test nattokinase or lumbrokinase.

Two questions remain open. First, whether enzymes taken by mouth reach the gut wall or bladder tissue in meaningful amounts is not established. Second, because many of these enzymes are digested like other proteins, taking them on an empty stomach is a clinical convention rather than a proven requirement. Despite the popular description, there are no published human trials that I know of showing that they "dissolve" biofilms in SIBO or UTI.

2. Divalent-Cation Chelators

If calcium, magnesium and iron help hold the matrix together, then binding those ions may weaken it. In laboratory flow-cell experiments, EDTA dispersed and killed P. aeruginosa cells in biofilms (Banin et al., 2006). In veterinary medicine, a single case report describes a dog with biofilm-associated recurrent E. coli cystitis treated with intravesical (in the bladder) EDTA-tromethamine alongside antibiotics (Leynaud et al., 2024).

These findings are interesting, but they do not show that oral or systemic EDTA works for SIBO or UTI in people. Chelating agents can also lower blood calcium, so the form, route and dose matter, and this belongs under clinician supervision.

3. Possible Quorum-Sensing Modulators (Targeted Herbs)

Bacteria do not build complex communities in isolation. They coordinate through a chemical communication system known as quorum sensing: signalling molecules called autoinducers let a population sense its own density and adjust behaviour, including biofilm formation (Mondal et al., 2025).

Several botanicals, including berberine, oregano oil, allicin (from garlic) and neem, have antibacterial or anti-biofilm activity in laboratory studies, and a review of plant extracts against uropathogenic E. coli has been published (Marouf et al., 2022). Whether they work specifically by blocking quorum-sensing receptors in the human body is still speculative.

4. Bladder Anti-Adhesion Agents

Uropathogenic E. coli use hair-like appendages called type 1 pili, tipped with an adhesin protein called FimH, to bind mannose residues on bladder cells (Qin et al., 2022). The idea behind D-mannose is that, as a free sugar, it acts as a decoy: FimH binds the free mannose instead of the bladder wall, and the bacteria are then flushed out in the urine.

Evidence for D-mannose is still evolving. One analysis of a non-interventional study of acute uncomplicated cystitis reported promising results, but it was a post hoc analysis and the authors describe their conclusions as preliminary (Wagenlehner et al., 2022). Cranberry products are better studied. The latest Cochrane review concluded that benefit appears in some groups, such as women with recurrent UTIs and children, but not in others (Williams et al., 2023). Cranberry proanthocyanidins are thought to interfere with the attachment of P-fimbriated E. coli rather than via FimH.

Importantly, anti-adhesion agents act on bacteria in the bladder lumen. They would not be expected to reach bacteria already inside the cells of the bladder wall, so they are best seen as supportive measures, not as a way to clear an intracellular reservoir.

A Practitioner's Approach to Sequencing (and the "Die-Off" Warning)

Some clinicians sequence biofilm disruptors and antimicrobials in stages. The timing described below reflects clinical practice and published practitioner protocols (Ruscio, 2026; Ruscio et al., 2025). To my knowledge, there are no controlled studies comparing different intervals. The specific timings (for example 30 to 60 minutes before antimicrobials) should be read as practitioner experience, not as an evidence-based standard.

Phase 1: Expose

In this approach, the biofilm disruptor (for example an enzyme or chelator) is taken first, usually on an empty stomach, so it does not compete with food proteins. The aim is to weaken the matrix before the antimicrobial is introduced. This is a clinical hypothesis, supported by laboratory data on matrix-degrading agents and chelators (Katsipis et al., 2025; Banin et al., 2006).

Phase 2: Attack

Some time after the disruptor, the patient takes the targeted herbal or pharmaceutical antimicrobial, such as berberine, allicin or rifaximin. The rationale is that a thinned matrix may allow better contact with the bacteria. The one retrospective chart review of adding a biofilm disruptor to herbal antimicrobials in SIBO and IMO concluded that adding biofilm disruption enhanced antimicrobial therapy (Ruscio et al., 2025). Because of its design (retrospective, single clinic), it cannot confirm that the combination, or the sequencing, is responsible.

Phase 3: Support and Flush

When bacteria die in large numbers, some people report a temporary worsening of symptoms, such as fatigue, brain fog, aches, or a flare in their gut or bladder symptoms. In clinical practice this is often called "die-off." The Jarisch-Herxheimer reaction is a well-recognised reaction after antibiotic treatment of spirochetal infections such as syphilis (Wood & Sbar, 2025). It is not established that SIBO or UTI treatments cause the same reaction, so "die-off" is best treated as a clinical description and not a proven mechanism.

Some clinicians add binders such as activated charcoal or bentonite clay to adsorb released material in the gut, often spaced one to two hours after antimicrobials. Evidence for this is limited, and there are no controlled data that I know of showing that binders prevent die-off symptoms in SIBO. Hydration is a reasonable, low-risk part of any urinary protocol. If symptoms are severe or do not settle, speak to your clinician and do not push through.

The Bottom Line: Is There Hope After Years of Relapse?

For the many people living in the exhausting loop of recurrent SIBO and chronic UTIs, the path to recovery can feel completely out of reach. Years of cycling through treatments, managing restrictive diets, and receiving negative lab results can leave patients feeling broken.

But the emerging science of biofilms offers a more hopeful way to look at it. "Chronic" does not have to mean permanent. It may simply mean that the current approach is not yet reaching the part of the problem that is keeping the cycle going.

The human body has a remarkable capacity for healing once the obstacles in its way are understood and addressed. A thoughtful, staged and clinician-guided approach, one that looks at the whole person and at the biology of persistence, offers a more compassionate and more informed way forward. The evidence is still developing, but your symptoms are real, and you deserve to be taken seriously.

Frequently Asked Questions

What is a biofilm in simple terms?

A biofilm is a community of microbes that attach to a surface and surround themselves with a self-made sticky matrix of sugars, proteins and DNA. This matrix can make the microbes harder for antibiotics and immune cells to reach (Di Martino, 2018; Zhao et al., 2023).

Do biofilms cause SIBO to come back?

This is a hypothesis. Biofilm-like layers have been observed in the ileum of some patients with IBS (Baumgartner & Gasche, 2025), but the link between biofilms, SIBO and relapse has not been proven, and the relationship between SIBO and IBS is still debated (Posserud et al., 2007).

Can a recurrent UTI be the same infection returning?

Sometimes. In many women, recurrences are caused by the same strain as the first infection (Rosen et al., 2007), and bacteria hiding inside bladder cells (intracellular bacterial communities) are one proposed reason (Kwak et al., 2024). Most of the detailed evidence comes from animal models.

Why can my urine culture be negative when I have symptoms?

Bacteria in biofilms or inside bladder cells may fall below the threshold of a standard urine culture (Scott et al., 2015). A negative culture is useful information, but it does not always explain persistent symptoms.

Do D-mannose and cranberry prevent UTIs?

The evidence is mixed. Cranberry products appear to help some groups, such as women with recurrent UTIs and children, but not others (Williams et al., 2023). Evidence for D-mannose is still emerging (Wagenlehner et al., 2022).

Are biofilm disruptors safe?

Safety depends on the agent, dose and your health and medicines. Enzymes can affect clotting, EDTA can lower calcium, and binders can reduce the absorption of medications and nutrients. Please discuss any protocol with a qualified clinician.

Take Your Next Step

If you would like to explore these ideas in more depth, here are two ways to continue:

Join the Chronic UTI Blueprint Audiobook Mini-Course & Companion Library

This audio mini-course offers an evidence-informed, step-by-step roadmap to help you understand recurrent infections, antibiotic resistance and biofilms, and to prepare for conversations with your clinician.

When you enrol, you will unlock:

🎧 The Complete Audio Masterclass: Narrated to walk you through antibiotic resistance, biofilm biology and recovery strategies.

📊 4 Interactive Diagnostic Workbooks: Step-by-step toolkits including Symptom Timeline Mapping and Biofilm Risk Scoring to help you organise your history and the questions to bring to your clinician.

🍳 3 Supportive Mini-Cookbooks: Bladder-friendly, anti-inflammatory dietary guides for morning, midday and evening.

🔗 Lifetime Companion Library Access: A secure link to your private digital resource hub with worksheets, daily tracking checklists and scientific citations.

Stop managing the symptoms of an old infection in the dark. Equip yourself with evidence-informed knowledge and practical tools to support a lasting path to health and wellness.

This article is for educational purposes only and is not a substitute for personalised medical advice, diagnosis or treatment. Always speak with a qualified healthcare professional about your symptoms and before starting any new supplement or protocol.

References

Abu Lila, A. S., Rajab, A. A. H., Abdallah, M. H., Rizvi, S. M. D., Moin, A., Khafagy, E. S., Tabrez, S., & Hegazy, W. A. H. (2023). Biofilm lifestyle in recurrent urinary tract infections. Life, 13(1), Article 148. https://doi.org/10.3390/life13010148

Banin, E., Brady, K. M., & Greenberg, E. P. (2006). Chelator-induced dispersal and killing of Pseudomonas aeruginosa cells in a biofilm. Applied and Environmental Microbiology, 72(3), 2064–2069. https://doi.org/10.1128/AEM.72.3.2064-2069.2006

Baumgartner, M., & Gasche, C. (2025). Ileal biofilms confirm SIBO–IBS hypothesis: Comment on PMID 38798120. Neurogastroenterology & Motility, 37(12), Article e70183. https://doi.org/10.1111/nmo.70183

Chedid, V., Dhalla, S., Clarke, J. O., Roland, B. C., Dunbar, K. B., Koh, J., Justino, E., Tomakin, E., & Mullin, G. E. (2014). Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. Global Advances in Health and Medicine, 3(3), 16–24. https://doi.org/10.7453/gahmj.2014.019

Di Martino, P. (2018). Extracellular polymeric substances, a key element in understanding biofilm phenotype. AIMS Microbiology, 4(2), 274–288. https://doi.org/10.3934/microbiol.2018.2.274

Gatta, L., & Scarpignato, C. (2017). Systematic review with meta-analysis: Rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Alimentary Pharmacology & Therapeutics, 45(5), 604–616. https://doi.org/10.1111/apt.13928

Katsipis, G., Aivaliotis, M., & Pantazaki, A. A. (2025). Serrapeptase eliminates Escherichia coli biofilms by targeting curli fibers, lipopolysaccharides, and phosphate metabolism. Microorganisms, 13(8), Article 1875. https://doi.org/10.3390/microorganisms13081875

Klingler, C. H. (2016). Glycosaminoglycans: How much do we know about their role in the bladder? Urologia, 83(Suppl. 1), 11–14. https://doi.org/10.5301/uro.5000184

Kwak, Y., Kim, H. G., Seok, J., Kim, S., Kim, E. M., & Kim, A. (2024). The critical role of intracellular bacterial communities in uncomplicated recurrent urinary cystitis: A comprehensive review of detection methods and diagnostic potential. International Neurourology Journal, 28(1), 4–10. https://doi.org/10.5213/inj.2448066.033

Leynaud, V., Jousserand, N. P., Lucas, M. N., Cavalié, L., Motta, J. P., Oswald, É., & Lavoué, R. (2024). Adjunctive intravesical EDTA-tromethamine treatment of a biofilm-associated recurrent Escherichia coli cystitis in a dog. The Canadian Veterinary Journal, 65(9), 886–893. https://pmc.ncbi.nlm.nih.gov/articles/PMC11339896/

Marouf, R. S., Mbarga, J. A. M., Ermolaev, A. V., Podoprigora, I. V., Smirnova, I. P., Yashina, N. V., Zhigunova, A. V., & Martynenkova, A. V. (2022). Antibacterial activity of medicinal plants against uropathogenic Escherichia coli. Journal of Pharmacy and Bioallied Sciences, 14(1), 1–12. https://doi.org/10.4103/jpbs.jpbs_124_21

Mondal, S., Melzi, A., Zecchin, S., & Cavalca, L. (2025). Quorum sensing in biofilm-mediated heavy metal resistance and transformation: Environmental perspectives and bioremediation. Frontiers in Microbiology, 16, Article 1607370. https://doi.org/10.3389/fmicb.2025.1607370

Poletajew, S., Brzózka, M. M., Krajewski, W., Kamecki, H., Nyk, Ł., & Kryst, P. (2024). Glycosaminoglycan replacement therapy with intravesical instillations of combined hyaluronic acid and chondroitin sulfate in patients with recurrent cystitis, post-radiation cystitis and bladder pain syndrome: A narrative review. Pain and Therapy, 13(1), 1–22. https://doi.org/10.1007/s40122-023-00559-1

Posserud, I., Stotzer, P.-O., Björnsson, E. S., Abrahamsson, H., & Simrén, M. (2007). Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut, 56(6), 802–808. https://doi.org/10.1136/gut.2006.108712

Qin, J., Wilson, K. A., Sarkar, S., Heras, B., O'Mara, M. L., & Totsika, M. (2022). Conserved FimH mutations in the global Escherichia coli ST131 multi-drug resistant lineage weaken interdomain interactions and alter adhesin function. Computational and Structural Biotechnology Journal, 20, 4532–4541. https://doi.org/10.1016/j.csbj.2022.08.040

Robinson, D., Toozs-Hobson, P., & Cardozo, L. (2013). The effect of hormones on the lower urinary tract. Menopause International, 19(4), 155–162. https://doi.org/10.1177/1754045313511398

Rosen, D. A., Hooton, T. M., Stamm, W. E., Humphrey, P. A., & Hultgren, S. J. (2007). Detection of intracellular bacterial communities in human urinary tract infection. PLoS Medicine, 4(12), Article e329. https://doi.org/10.1371/journal.pmed.0040329

Ruscio, M. (2026, April 22). SIBO biofilm explained: Symptoms, causes, and a treatment protocol. Dr. Michael Ruscio, DC. https://drruscio.com/sibo-biofilm/

Ruscio, M., Guard, G., O'Dwyer, D., Darville, R., Klopf, H., Abbott, R., & Spiridigliozzi, S. (2025). Biofilm disruption enhances antimicrobial therapy for small intestinal bacterial overgrowth and intestinal methanogen overgrowth. Cureus, 17(12), Article e99116. https://doi.org/10.7759/cureus.99116

Schulze, A., Mitterer, F., Pombo, J. P., & Schild, S. (2021). Biofilms by bacterial human pathogens: Clinical relevance – Development, composition and regulation – Therapeutical strategies. Microbial Cell, 8(2), 28–56. https://doi.org/10.15698/mic2021.02.741

Scott, V. C. S., Haake, D. A., Churchill, B. M., Justice, S. S., & Kim, J.-H. (2015). Intracellular bacterial communities: A potential etiology for chronic lower urinary tract symptoms. Urology, 86(3), 425–431. https://doi.org/10.1016/j.urology.2015.04.002

Wagenlehner, F., Lorenz, H., Ewald, O., & Gerke, P. (2022). Why d-mannose may be as efficient as antibiotics in the treatment of acute uncomplicated lower urinary tract infections—Preliminary considerations and conclusions from a non-interventional study. Antibiotics, 11(3), Article 314. https://doi.org/10.3390/antibiotics11030314

Williams, G., Stothart, C. I., Hahn, D., Stephens, J. H., Craig, J. C., & Hodson, E. M. (2023). Cranberries for preventing urinary tract infections. Cochrane Database of Systematic Reviews, 2023(11), Article CD001321. https://doi.org/10.1002/14651858.CD001321.pub7

Wood, J. M., & Sbar, E. (2025). Jarisch-Herxheimer reaction. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK557820/

Zhao, A., Sun, J., & Liu, Y. (2023). Understanding bacterial biofilms: From definition to treatment strategies. Frontiers in Cellular and Infection Microbiology, 13, Article 1137947. https://doi.org/10.3389/fcimb.2023.1137947

AI disclosure

This article reflects the author's own clinical experience, ideas, and perspective. Claude (Anthropic) was used for editorial support in preparing this piece - including research assistance, citation verification, and structural polishing.

📬 Subscribe for Deeper Insights: Join our community to receive evidence-informed research updates, practical health insights and case-based learning straight to your inbox.